Evidence map›Paper›PMID 33825986›Full record

SynthesisWorld journal of urology2021

A systematic review and meta-analysis of Histoscanning™ in prostate cancer diagnostics.

Andrey Morozov, Vasiliy Kozlov, Juan Gomez Rivas, Jeremy Yuen-Chun Teoh, Evgeniy Bezrukov, Alexander Amosov, Eric Barret, Mark Taratkin, Georg Salomon, Thomas R W Herrmann and 3 more

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Andrey MorozovInstitute for Urology and Reproductive Health, Sechenov University, Bolshaya Pirogovskaya str. 2 bld. 1, Moscow, 119991, Russia.
Vasiliy KozlovDepartment of Public Health and Healthcare, Sechenov University, Moscow, Russia.
Juan Gomez RivasDepartment of Urology, Clinico San Carlos University Hospital, Madrid, Spain.
Jeremy Yuen-Chun TeohDepartment of Surgery, S.H. Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China.
Evgeniy BezrukovInstitute for Urology and Reproductive Health, Sechenov University, Bolshaya Pirogovskaya str. 2 bld. 1, Moscow, 119991, Russia.
Alexander AmosovInstitute for Urology and Reproductive Health, Sechenov University, Bolshaya Pirogovskaya str. 2 bld. 1, Moscow, 119991, Russia.
Eric BarretDepartment of Urology, Institut Mutualiste Montsouris, Paris, France.
Mark TaratkinInstitute for Urology and Reproductive Health, Sechenov University, Bolshaya Pirogovskaya str. 2 bld. 1, Moscow, 119991, Russia.
Georg SalomonMartini Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thomas R W HerrmannDepartment of Urology, Spital Thurgau AG, Pfaffenholzstrasse 4, 8501, Frauenfeld, Switzerland.
Ali GozenSLK-Kliniken Urology Department, Heidelberg University, Heilbronn, Germany.
Dmitry EnikeevInstitute for Urology and Reproductive Health, Sechenov University, Bolshaya Pirogovskaya str. 2 bld. 1, Moscow, 119991, Russia. dvenikeev@gmail.com.ORCID http://orcid.org/0000-0001-7169-2209
collaboration between ESUT, ESUI and Uro-technology WP of the Young Academic Urologists

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextThe value of Histoscanning™ (HS) in prostate cancer (PCa) imaging is much debated, although it has been used in clinical practice for more than 10 years now.

objectiveTo summarize the data on HS from various PCa diagnostic perspectives to determine its potential. MATERIALS AND

methodsWe performed a systematic search using 2 databases (Medline and Scopus) on the query "Histoscan*". The primary endpoint was HS accuracy. The secondary endpoints were: correlation of lesion volume by HS and histology, ability of HS to predict extracapsular extension or seminal vesicle invasion.

resultsHS improved cancer detection rate "per core", OR = 16.37 (95% CI 13.2; 20.3), p < 0.0001, I

conclusionThis meta-analysis does not see the incremental value in comparing prostate Histoscanning with conventional TRUS in prostate cancer screening and targeted biopsy. HS proved to be slightly more accurate in predicting extracapsular extension on RP, but the available data does not allow us to draw any conclusions on its effectiveness in practice. Histoscanning is a modification of ultrasound for prostate cancer visualization. The available data suggest its low accuracy in screening and detecting of prostate cancer.

Indexed as

UltrasonographyBiopsy, Large-Core NeedleHumansMaleNeoplasm InvasivenessOdds RatioProstatic NeoplasmsSeminal VesiclesSensitivity and SpecificityTumor BurdenHistoscanningImagingProstate cancerSystematic reviewUltrasound

Identifiers

PMID33825986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.